KR102925388B1 - 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물 - Google Patents

안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물

Info

Publication number
KR102925388B1
KR102925388B1 KR1020197029676A KR20197029676A KR102925388B1 KR 102925388 B1 KR102925388 B1 KR 102925388B1 KR 1020197029676 A KR1020197029676 A KR 1020197029676A KR 20197029676 A KR20197029676 A KR 20197029676A KR 102925388 B1 KR102925388 B1 KR 102925388B1
Authority
KR
South Korea
Prior art keywords
chamber
cells
tumor
igf
odn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197029676A
Other languages
English (en)
Korean (ko)
Other versions
KR20190140440A (ko
Inventor
데이비드 더블유 앤드루스
더글라스 씨 후퍼
Original Assignee
토마스 제퍼슨 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 토마스 제퍼슨 유니버시티 filed Critical 토마스 제퍼슨 유니버시티
Priority to KR1020247023860A priority Critical patent/KR20240116561A/ko
Publication of KR20190140440A publication Critical patent/KR20190140440A/ko
Application granted granted Critical
Publication of KR102925388B1 publication Critical patent/KR102925388B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
KR1020197029676A 2017-03-09 2018-03-09 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물 Active KR102925388B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247023860A KR20240116561A (ko) 2017-03-09 2018-03-09 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762469003P 2017-03-09 2017-03-09
US62/469,003 2017-03-09
US201862629972P 2018-02-13 2018-02-13
US62/629,972 2018-02-13
PCT/US2018/021706 WO2018165528A1 (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023860A Division KR20240116561A (ko) 2017-03-09 2018-03-09 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20190140440A KR20190140440A (ko) 2019-12-19
KR102925388B1 true KR102925388B1 (ko) 2026-02-11

Family

ID=62838976

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197029676A Active KR102925388B1 (ko) 2017-03-09 2018-03-09 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물
KR1020247023860A Pending KR20240116561A (ko) 2017-03-09 2018-03-09 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247023860A Pending KR20240116561A (ko) 2017-03-09 2018-03-09 안티센스를 사용하여 암을 치료하기 위한 방법 및 조성물

Country Status (14)

Country Link
US (5) US10357509B2 (https=)
EP (2) EP4378531A3 (https=)
JP (3) JP7681285B2 (https=)
KR (2) KR102925388B1 (https=)
CN (2) CN118750590A (https=)
AU (2) AU2018230458B2 (https=)
BR (1) BR112019018555A2 (https=)
CA (1) CA3054662A1 (https=)
IL (2) IL316679A (https=)
MX (2) MX2019010725A (https=)
NZ (1) NZ756820A (https=)
RU (1) RU2766457C2 (https=)
SG (2) SG11201908054XA (https=)
WO (1) WO2018165528A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164916A1 (en) * 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
CN108291227A (zh) 2015-10-14 2018-07-17 拜奥-帕斯控股股份有限公司 用于脂质体制剂的对乙氧基核酸
AU2017325971A1 (en) 2016-09-16 2019-04-11 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
US10357509B2 (en) 2017-03-09 2019-07-23 Thomas Jefferson University Methods and compositions for treating cancers using antisense
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
EA201992485A1 (ru) 2017-04-19 2020-02-17 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования stat3
CA3089583A1 (en) * 2018-01-24 2019-08-01 Thomas Jefferson University Biodiffusion chamber
CA3113812A1 (en) * 2018-09-26 2020-04-02 Thomas Jefferson University Neoantigen compositions; and methods of preparation and use thereof
EP3873497A4 (en) * 2018-11-02 2022-08-03 Thomas Jefferson University METHODS AND COMPOSITIONS FOR THE TREATMENT OF BREAST CANCER USING ANTISENSE NUCLEIC ACIDS
AU2019374061A1 (en) * 2018-11-02 2021-06-03 Thomas Jefferson University Methods and compositions for treating hepatocellular carcinoma using antisense
MX2021011760A (es) * 2019-03-28 2021-12-10 Univ Jefferson Metodos para el tratamiento de canceres usando antisentido.
USD1107915S1 (en) 2019-07-23 2025-12-30 Thomas Jefferson University Biodiffusion chamber
WO2024077130A1 (en) * 2022-10-05 2024-04-11 Thomas Jefferson University Methods and compositions for treating bladder cancer
TW202546228A (zh) * 2024-01-19 2025-12-01 大陸商維亞臻生物技術（蘇州）有限公司 用於抑制胰島素樣生長因子１受體表達的ｒｎａ抑制劑

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206286A1 (en) 2006-09-26 2008-08-28 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2010028820A2 (en) 2008-09-10 2010-03-18 Life & Brain Gmbh Peripheral zone tumor cells, methods for their preparation and use
US20170056430A1 (en) * 2015-04-10 2017-03-02 Thomas Jefferson University Methods and Compositions for Treating Cancers and Enhancing Therapeutic Immunity by Selectively Reducing Immunomodulatory M2 Monocytes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750516A4 (en) 1993-03-26 1998-07-01 Univ Jefferson METHOD FOR INHIBITING CELL PROLIFERATION AND TRIGGERING CELL DIFFERENTIATION USING TYPE 1 GROWTH FACTOR RECEPTOR OLIGONUCLEOTIDES
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5714170A (en) 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US6541036B1 (en) 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
JP2002522506A (ja) * 1998-08-13 2002-07-23 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子−ｉ受容体に向けられるオリゴヌクレオチドを用いた腫瘍の処置
US6144553A (en) 1998-09-09 2000-11-07 Sun Microsystems, Inc. Refrigeration cooled disk storage assembly
US7037335B2 (en) 2002-11-19 2006-05-02 Eagle Vision, Inc. Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma
WO2004072284A1 (en) 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
ES2677070T3 (es) * 2010-10-27 2018-07-27 Curna, Inc. Tratamiento de enfermedades relacionadas con el regulador del desarrollo 1 asociado a interferón (ifrd1) mediante inhibición del transcrito antisentido natural al gen ifrd1
CN105792775B (zh) 2013-09-24 2019-02-19 吉纳生命科学公司 用于细胞植入物的气体处理的系统
US9872674B2 (en) 2014-05-07 2018-01-23 Boehringer Laboratories Inc. Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure
CA3250034A1 (en) * 2015-04-23 2025-10-30 Applied Medical Resources Corporation Systems and methods for tissue removal
CN108291227A (zh) 2015-10-14 2018-07-17 拜奥-帕斯控股股份有限公司 用于脂质体制剂的对乙氧基核酸
US10357509B2 (en) 2017-03-09 2019-07-23 Thomas Jefferson University Methods and compositions for treating cancers using antisense
CA3089583A1 (en) * 2018-01-24 2019-08-01 Thomas Jefferson University Biodiffusion chamber

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206286A1 (en) 2006-09-26 2008-08-28 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2010028820A2 (en) 2008-09-10 2010-03-18 Life & Brain Gmbh Peripheral zone tumor cells, methods for their preparation and use
US20170056430A1 (en) * 2015-04-10 2017-03-02 Thomas Jefferson University Methods and Compositions for Treating Cancers and Enhancing Therapeutic Immunity by Selectively Reducing Immunomodulatory M2 Monocytes

Also Published As

Publication number Publication date
KR20240116561A (ko) 2024-07-29
KR20190140440A (ko) 2019-12-19
EP4378531A3 (en) 2024-09-04
IL316679A (en) 2024-12-01
JP2025085731A (ja) 2025-06-05
US20190365794A1 (en) 2019-12-05
CN118750590A (zh) 2024-10-11
WO2018165528A1 (en) 2018-09-13
EP3592841A1 (en) 2020-01-15
IL268872B1 (en) 2024-12-01
RU2019130010A3 (https=) 2021-07-05
EP3592841B1 (en) 2024-02-14
MX2019010725A (es) 2020-02-10
JP7681285B2 (ja) 2025-05-22
RU2019130010A (ru) 2021-04-10
JP2020510021A (ja) 2020-04-02
AU2024227517A1 (en) 2024-11-14
US10357509B2 (en) 2019-07-23
JP7656350B2 (ja) 2025-04-03
SG10202109912XA (en) 2021-10-28
AU2018230458A1 (en) 2019-09-05
IL268872A (en) 2019-10-31
EP3592841A4 (en) 2021-01-06
US10772904B2 (en) 2020-09-15
CN110832068A (zh) 2020-02-21
US20180256625A1 (en) 2018-09-13
US11801259B2 (en) 2023-10-31
AU2018230458B2 (en) 2024-11-21
US20180201939A1 (en) 2018-07-19
NZ756820A (en) 2022-08-26
US20210060055A1 (en) 2021-03-04
BR112019018555A2 (pt) 2020-04-14
JP2023081916A (ja) 2023-06-13
US20240100078A1 (en) 2024-03-28
IL268872B2 (en) 2025-04-01
RU2766457C2 (ru) 2022-03-15
SG11201908054XA (en) 2019-09-27
MX2024008496A (es) 2024-07-15
CA3054662A1 (en) 2018-09-13
EP4378531A2 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
JP7656350B2 (ja) アンチセンスを用いて癌を治療するための方法及び組成物
JP2025098027A (ja) アンチセンスを用いてがんを治療するための方法
JP2024163121A (ja) アンチセンスを使用した肝細胞癌治療用の方法および組成物
JP2025010156A (ja) アンチセンスを使用した乳癌治療用の方法および組成物
HK40112216A (en) Methods and compositions for treating cancers using antisense
HK40022361B (en) Compositions for treating cancers using antisense
HK40022361A (en) Compositions for treating cancers using antisense
BR122025011178A2 (pt) Métodos e composições para tratamento de cânceres utilizando antissenso

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20250930

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2019 7029676

Appeal request date: 20240716

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101001577

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2024101001577; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : APPEAL AGAINST DECISION TO DECLINE REFUSAL

E12 Pre-grant re-examination requested

Free format text: ST27 STATUS EVENT CODE: A-6-3-E10-E12-REX-PS0901 (AS PROVIDED BY THE NATIONAL OFFICE)

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PS0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)